Is your skin blemish a health risk?
Could it be skin cancer? Perform a self-check in minutes.
Use Skinapp Checker, and receive an assessment of your skin moles before your doctor’s appointment.
Skinapp Checker: Always be sure
The skin is the largest organ in the human body and its primary protective layer. As a result, it’s always at risk of various types of bruising, discoloration, and lesions from superficial damage.
But sometimes, changes in the skin are symptomatic of a more serious problem that should not be ignored. For example, the early detection of melanoma, one of the most aggressive skin cancers, saves lives and significantly increases the chances of recovery.
So what should you do?
The Skinapp Checker application, using the most advanced technologies, was specifically designed to meet the need for immediate, independent, and intelligent identification of suspicious moles and skin lesions. You can easily check yourself at anytime, anywhere, and get an artificial intelligence-driven assessment at the click of a button.
All you have to do is take a picture of the lesion. Skinapp will determine the nature of the lesion and provide you with a risk assessment. When necessary, the app will recommend that you obtain medical advice from a professional healthcare provider. Take pictures of the lesion over time, and the system will identify suspicious changes and make a recommendation regarding next steps.
Skinapp Checker, the optimal solution for self-examination, was created with the vision of reducing the impact of various skin diseases through early, easy and independent detection. In doing so, it is directly contributing to the overall health of each and every one of us.
The innovative technology behind Skinapp Checker is a product of research conducted at the Hebrew University of Jerusalem in Israel and has been granted multiple patents.
The unique value of Skinapp Checker.
Assessments driven by artificial intelligence
A massive database of lesions and moles
Uses your smartphone’s built-in camera
Immediate answers at the click of a button
Monitors skin aberrations for changes over time
Allows consultation with a dermatologist directly through the app
Visual comparison of similar lesions produces a high degree of certainty
Easy to download and use
Always available on your mobile
Assessments driven by artificial intelligence
A massive database of lesions and moles
Immediate answers at the click of a button
Uses your smartphone’s camera
Monitors skin aberrations for changes over time
Allows consultation with a dermatologist directly through the app
User friendly
Visual comparison of similar lesions produces a high degree of accuracy
Available on your computer or mobile
Early detection saves lives!
How To Use Skinapp
Team
Dr. Gil Pogozelich
Chairman
Over 20 years experience leading successful start-ups in various technology fields. Chairman of the Goldman Group, specializing in development, integration and commercialization of life sciences technologies, with an emphasis on personalized medicine.
Dr. Steven Hubert MD
Medical Director
Dr. Hubert is a certified member of the American Board of Dermatology, with over 20 years of clinical and surgical experience in the United States. He served as chief of the Dermatology Section at the University Medical Center at Princeton and Capital Health Hospitals, and currently works at several medical centers in New Jersey.
Dr. Yoav Smith
VP of Technology
Director of the Genomic Data Analysis Unit at the Hebrew University of Jerusalem, and a lecturer in the field of data analysis and visualization. A Technion graduate and a Kaye Award winner, he has published over 40 articles and registered numerous data analytics patents.
Maor Cohen
VP of Engineering and System Architect
Over 10 years of experience in the high-tech sector. Trained at the IDF’s Center for Computing and Information Systems (Mamram), he served in the Central Technology Unit of the Intelligence Corps. He also graduated with honors from the Weizmann Institute of Science’s Young Researcher Program in the field of immunology.
Dr. Gil Pogozelich
Dr. Gil Pogozelich
Over 20 years experience leading successful start-ups in various technology fields. Chairman of the Goldman Group, specializing in development, integration and commercialization of life sciences technologies, with an emphasis on personalized medicine.
Dr. Steven Hubert
Dr. Steven Hubert
Dr. Hubert is a certified member of the American Board of Dermatology, with over 20 years of clinical and surgical experience in the United States. He served as chief of the Dermatology Section at the University Medical Center at Princeton and Capital Health Hospitals, and currently works at several medical centers in New Jersey.
Dr. Yoav Smith
Dr. Yoav Smith
Director of the Genomic Data Analysis Unit at the Hebrew University of Jerusalem, and a lecturer in the field of data analysis and visualization. A Technion graduate and a Kaye Award winner, he has published over 40 articles and registered numerous data analytics patents.
Mr. Maor Cohen
Maor Cohen
Over 10 years of experience in the high-tech sector. Trained at the IDF’s Center for Computing and Information Systems (Mamram), he served in the Central Technology Unit of the Intelligence Corps. He also graduated with honors from the Weizmann Institute of Science’s Young Researcher Program in the field of immunology.
Patents
- Model system for TCR zeta (ƺ) chain down-regulation
EP1708565/ IL158011 – Granted.(France, Germany, Luxemburg) - Kit/Method for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases
US9188588/ EP2274615/ IL208544 – Granted. (USA, France, Germany, Luxemburg, Switzerland, United Kingdom, Israel)
US20160209424(CIP)- Under Examination. (USA) - CD247 as a biomarker for assessing the effect of chemotherapeutic and biological drugs
EP2834640- Granted. (Europe). US20170370932 – Under Examination (USA) - SNX9 as a novel Biomarker for Chronic Inflammation and associated Immunosuppression and a new Regulator of T cell Receptor Expression and Function
EP2671079/ IL227694 – Granted.(France, Germany, Switzerland, United Kingdom, Israel). US20140037659 – Under Examination (USA) - Methods for prediction and monitoring cancer patients` response to treatment by measuring Myeloid Derived Suppressor Cells (MDSCs)
EP3215844-Granted. (Europe). US2017261507 Under Examination-(USA)
Press
